REGENXBIO Inc.

Day range

$7.48 – $7.96

Open

$7.72

Prev close

$7.63

Volume

587.96K

Market cap

$503.68M

Shares out

66.01M

P/E

—

P/S

2.89

P/B

7.02

P/FCF

—

ROE

-273.7%

ROA

-50.8%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 3, 2026

• Director departureOct 16, 2026

  On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the "Board") of REGENXBIO Inc. (the "Company") effective October 21, 2026. Mr. Mills recently became chief executive officer of another company and intends to focus his efforts on his new role. Mr. Mills' decision was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices.

• Settlement agreementSep 23, 2026

  On September 23, 2026, REGENXBIO Inc. and The Trustees of the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC and Catalent, Inc. to resolve all patent infringement litigation alleging infringement of U.S. Patent Nos. 10,526,617 and 11,680,274 related to Sarepta’s manufacture, use, offer to sell and sale of SRP-9001 (also known as ELEVIDYS® in the U.S.).

• Director departureAug 25, 2026

  On August 25, 2026, the Board also accepted the resignation of Jean Bennett, M.D., Ph.D. and A.N. "Jerry" Karabelas, Ph.D. from their positions as directors of the Company, effective August 25, 2026. Dr. Bennett and Dr. Karabelas will serve as advisors to the Company to assist the Board until February 2027, unless further extended.

• Regulatory decisionAug 24, 2026

  the Company received communication from the U.S. Food and Drug Administration ("FDA") that the Company's Investigational New Drug application for its Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis type II ("MPS II"), also known as Hunter Syndrome, was placed on clinical hold and that the Company does not expect to resubmit the RGX-121 Biologics License Application ("BLA") in the near term.

• Underwriting agreementJul 20, 2026

  On July 16, 2026, REGENXBIO Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Leerink Partners LLC and Mizuho Securities USA LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the offer and sale of 10,003,889 shares of the Company's common stock.

Days to cover

6.8

Short interest

10.04M

Avg volume

1.48M

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?
  positiveZacks Investment Research· Nov 4, 2026
• Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
  negativeGlobeNewswire Inc.· Jul 13, 2026
• Diabetic Retinopathy Pipeline Insight 2026: Comprehensive Analysis of 50+ Companies and 55+ Drugs in Development
  positiveGlobeNewswire Inc.· Jul 3, 2026
• Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
  positiveGlobeNewswire Inc.· Jun 18, 2026
• REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX
  negativeBenzinga· Apr 14, 2026